{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:43Z","timestamp":1793155783848,"version":"4.5.0"},"reference-count":65,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Psoriasis and psoriatic arthritis are chronic immune-mediated disorders with involvement of interleukin (IL)-17 cytokines in their pathogenesis. IL-17A has been considered to be the most biologically active, but IL-17F is also over-expressed in skin and synovial tissues of patients with these diseases. Many therapeutic advances have been made in the past years, but some needs remain unmet. Dual inhibitor and bispecific antibodies simultaneously targeting IL-17A and IL-17F could provide better disease control. Herein we review current evidence on bimekizumab and sonelokimab. The antigen-binding site of bimekizumab neutralizes both IL-17A and IL-17F; phase I, II, and III studies have demonstrated its efficacy and safety in psoriasis and psoriatic arthritis. Sonelokimab is a trivalent nanobody targeting IL-17A and IL-17F; phase I and II studies with this molecule have yielded promising results in psoriasis.<\/jats:p>","DOI":"10.1177\/20406223211037846","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T07:14:10Z","timestamp":1628752450000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":52,"title":["Dual inhibition of IL-17A and IL-17F in psoriatic disease"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-5521","authenticated-orcid":false,"given":"Helena","family":"Iznardo","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret, 167, Barcelona 08025, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"bibr1-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"bibr2-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1537"},{"key":"bibr3-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013"},{"key":"bibr4-20406223211037846","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3375"},{"key":"bibr5-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.027"},{"key":"bibr6-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"bibr7-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"bibr8-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.02.012"},{"key":"bibr9-20406223211037846","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.11.6173"},{"key":"bibr10-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1002\/art.40770"},{"key":"bibr11-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700499200"},{"key":"bibr12-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2007.35"},{"key":"bibr13-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(14)70015-8"},{"key":"bibr14-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028522"},{"key":"bibr15-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"bibr16-20406223211037846","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010046"},{"key":"bibr17-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.194"},{"key":"bibr18-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0426-z"},{"key":"bibr19-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x"},{"key":"bibr20-20406223211037846","unstructured":"Drug information: Taltz. taltz-epar-product-information_es.pdf. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_es.pdf (accessed 18 April 2021)."},{"key":"bibr21-20406223211037846","unstructured":"Drug information: Cosentyx. cosentyx-epar-product-information_es.pdf. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_es.pdf (accessed 18 April 2021)."},{"key":"bibr22-20406223211037846","unstructured":"Drug information: Kyntheum. kyntheum-epar-product-information_es.pdf. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyntheum-epar-product-information_es.pdf (accessed 25 April 2021)."},{"key":"bibr23-20406223211037846","unstructured":"Kyowa Kirin. LUMICEF\n                      \u00ae\n                      approved in Japan. https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2016\/e20160704_01.html (accessed 25 April 2021)."},{"key":"bibr24-20406223211037846","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894"},{"key":"bibr25-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.056"},{"key":"bibr26-20406223211037846","first-page":"29","volume":"9","author":"Chiricozzi A","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"bibr27-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"bibr28-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"bibr29-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214943"},{"key":"bibr30-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.105"},{"key":"bibr31-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"key":"bibr32-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7"},{"key":"bibr33-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"bibr34-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"bibr35-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021"},{"key":"bibr36-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13185"},{"key":"bibr37-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"bibr38-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"bibr39-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30220-8"},{"key":"bibr40-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4204"},{"key":"bibr41-20406223211037846","unstructured":"Merola J, Behrens F, Kivitz A, et al. Bimekizumab maintenance of response in patients with psoriatic arthritis: 2-year results from a phase 2b dose-ranging study and its open-label extension. Arthritis Rheumatol. https:\/\/acrabstracts.org\/abstract\/bimekizumab-maintenance-of-response-in-patients-with-psoriatic-arthritis-2-year-results-from-a-phase-2b-dose-ranging-study-and-its-open-label-extension\/ (2020, accessed 25 April 2021)."},{"key":"bibr42-20406223211037846","unstructured":"UCB Biopharma SRL. A multicenter, open-label, follow-up study to evaluate the long-term safety and efficacy of bimekizumab in subjects with psoriatic arthritis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03347110 (2021, accessed 22 April 2021)."},{"key":"bibr43-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1850"},{"key":"bibr44-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.01.014"},{"key":"bibr45-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00361-6"},{"key":"bibr46-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2016.10.019"},{"key":"bibr47-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2"},{"key":"bibr48-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1187130"},{"key":"bibr49-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1093266"},{"key":"bibr50-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0580-y"},{"key":"bibr51-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1002\/art.40579"},{"key":"bibr52-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key312"},{"key":"bibr53-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzv034"},{"key":"bibr54-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200439"},{"key":"bibr55-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13814"},{"key":"bibr56-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.12989"},{"key":"bibr57-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191397"},{"key":"bibr58-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.12.026"},{"key":"bibr59-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1538351"},{"key":"bibr60-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01907-y"},{"key":"bibr61-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1730326"},{"key":"bibr62-20406223211037846","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S267405"},{"key":"bibr63-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00269-5"},{"key":"bibr64-20406223211037846","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.20.06580-3"},{"key":"bibr65-20406223211037846","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015"}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223211037846","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223211037846","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223211037846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:35Z","timestamp":1777591115000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223211037846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":65,"alternative-id":["10.1177\/20406223211037846"],"URL":"https:\/\/doi.org\/10.1177\/20406223211037846","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"20406223211037846"}}